Immunochemical studies of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1 O-specific polysaccharide-core fragments and their protein conjugates as vaccine candidates
- PMID: 20542498
- PMCID: PMC2902686
- DOI: 10.1016/j.carres.2010.05.006
Immunochemical studies of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1 O-specific polysaccharide-core fragments and their protein conjugates as vaccine candidates
Abstract
There is no licensed vaccine for the prevention of shigellosis. Our approach to the development of a Shigella vaccines is based on inducing serum IgG antibodies to the O-specific polysaccharide (O-SP) domain of their lipopolysaccharides (LPS). We have shown that low molecular mass O-SP-core (O-SPC) fragments isolated from Shigella sonnei LPS conjugated to proteins induced significantly higher antibody levels in mice than the full length O-SP conjugates. This finding is now extended to the O-SPC of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1. The structures of O-SPC, containing core plus 1-4 O-SP repeat units (RUs), were analyzed by NMR and mass spectroscopy. The first RUs attached to the cores of S. flexneri 2a and 6 LPS were different from the following RUs in their O-acetylation and/or glucosylation. Conjugates of core plus more than 1 RU were necessary to induce LPS antibodies in mice. The resulting antibody levels were comparable to those induced by the full length O-SP conjugates. In S. dysenteriae type 1, the first RU was identical to the following RUs, with the exception that the GlcNAc was bound to the core in the beta-configuration, while in all other RUs the GlcNAc was present in the alpha-configuration. In spite of this difference, conjugates of S. dysenteriae type 1 core with 1, 2, or 3 RUs induced LPS antibodies in mice with levels statistically higher than those of the full size O-SP conjugates. O-SPC conjugates are easy to prepare, characterize, and standardize, and their clinical evaluation is planned.
Published by Elsevier Ltd.
Figures





Similar articles
-
Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.Infect Immun. 1993 Sep;61(9):3678-87. doi: 10.1128/iai.61.9.3678-3687.1993. Infect Immun. 1993. PMID: 8359890 Free PMC article.
-
Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates.Proc Natl Acad Sci U S A. 2009 May 12;106(19):7974-8. doi: 10.1073/pnas.0900891106. Epub 2009 Apr 3. Proc Natl Acad Sci U S A. 2009. PMID: 19346477 Free PMC article.
-
Expression of Shigella dysenteriae serotype 1 O-antigenic polysaccharide by Shigella flexneri aroD vaccine candidates and different S. flexneri serotypes.J Bacteriol. 1995 Sep;177(18):5310-5. doi: 10.1128/jb.177.18.5310-5315.1995. J Bacteriol. 1995. PMID: 7545156 Free PMC article.
-
Detoxified O-Specific Polysaccharide (O-SP)-Protein Conjugates: Emerging Approach in the Shigella Vaccine Development Scene.Vaccines (Basel). 2022 Apr 24;10(5):675. doi: 10.3390/vaccines10050675. Vaccines (Basel). 2022. PMID: 35632431 Free PMC article. Review.
-
Shigellosis in Vietnam: seroepidemiologic studies with use of lipopolysaccharide antigens in enzyme immunoassays.Rev Infect Dis. 1991 Mar-Apr;13 Suppl 4:S231-7. doi: 10.1093/clinids/13.supplement_4.s231. Rev Infect Dis. 1991. PMID: 2047643 Review.
Cited by
-
Comparison and Optimization of Quantification Methods for Shigella flexneri Serotype 6 O-antigen Containing Galacturonic Acid and Methyl-Pentose.Int J Mol Sci. 2021 Nov 10;22(22):12160. doi: 10.3390/ijms222212160. Int J Mol Sci. 2021. PMID: 34830042 Free PMC article.
-
Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.Vaccine. 2024 Oct 24;42(24):126263. doi: 10.1016/j.vaccine.2024.126263. Epub 2024 Aug 31. Vaccine. 2024. PMID: 39217775
-
Overexpression of O-polysaccharide chain length regulators in Gram-negative bacteria using the Wzx-/Wzy-dependent pathway enhances production of defined modal length O-polysaccharide polymers for use as haptens in glycoconjugate vaccines.J Appl Microbiol. 2018 Aug;125(2):575-585. doi: 10.1111/jam.13772. Epub 2018 May 15. J Appl Microbiol. 2018. PMID: 29603538 Free PMC article.
-
Toward a Shigella Vaccine: Opportunities and Challenges to Fight an Antimicrobial-Resistant Pathogen.Int J Mol Sci. 2023 Feb 28;24(5):4649. doi: 10.3390/ijms24054649. Int J Mol Sci. 2023. PMID: 36902092 Free PMC article. Review.
-
Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human.Hum Vaccin Immunother. 2019;15(6):1338-1356. doi: 10.1080/21645515.2019.1606972. Hum Vaccin Immunother. 2019. PMID: 31158047 Free PMC article. Review.
References
-
- Guerrant RL, Kirchhoff LV, Shields DS, Nations MK, Leslie J, de Sousa MA, Araujo JG, Correia LL, Sauer KT, McClelland KE. J. Infect. Dis. 1983;148:986–997. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources